Armata Pharmaceuticals
ARMP
23 hedge funds and large institutions have $3.85M invested in Armata Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.
185% more capital invested
Capital invested by funds: $1.35M → $3.85M (+$2.49M)
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
5% more funds holding
Funds holding: 22 → 23 (+1)
0.27% more ownership
Funds ownership: 3.28% → 3.55% (+0.27%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$211K |
| 2 |
State Street
Boston,
Massachusetts
|
+$108K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$83.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$6.03K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$5.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$89.3K |
| 2 |
HF
HRT Financial
New York
|
-$22K |
| 3 |
Renaissance Technologies
New York
|
-$13.1K |
| 4 |
BlackRock
New York
|
-$3.73K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$276 |
ARMP Hedge Fund Activity: Q3 2023 in Review
23 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q3 2023, worth a combined $3.85M — up 185% from $1.35M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ARMP positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $211K. The largest seller was Bridgeway Capital Management, cutting an estimated $89.3K.
- 23 institutional investors held Armata Pharmaceuticals (ARMP) as of Q3 2023, up from 22 in Q2 2023.
- Funds reported $3.85M of Armata Pharmaceuticals stock for Q3 2023, up 185% quarter-over-quarter.
- 4 funds opened new Armata Pharmaceuticals positions in Q3 2023 and 3 closed out, a net change of +1 holder.
- The largest Armata Pharmaceuticals buyer in Q3 2023 was Geode Capital Management, an estimated $211K added.
- The largest Armata Pharmaceuticals seller in Q3 2023 was Bridgeway Capital Management, an estimated $89.3K sold.
Based on aggregated 13F filings for Q3 2023.